Gene Expression Score May Guide Treatment in Uveal Melanoma
A gene expression score may be able to predict outcomes of adoptive cell therapy and prevent unnecessary surgeries in patients with uveal melanoma, researchers say.
A gene expression score may be able to predict outcomes of adoptive cell therapy and prevent unnecessary surgeries in patients with uveal melanoma, researchers say.
Abstract. Many cancer patients are at risk of developing cognitive symptoms that often become evident during or after cancer-directed therapy and may involve difficulties with…
Our providers at Fred Hutchinson Cancer Center partner with UW Medicine for skin and mole screenings.
On May 15, 2024, the FDA granted accelerated approval to lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adults with follicular lymphoma.
The repositioning of shelved assets for pediatric applications presents a promising avenue for advancing therapies for childhood tumors. Tovorafenib, originally intended for adult melanoma, received…
The FDA granted accelerated approval to lisocabtagene maraleucel for treatment of adults with relapsed or refractory follicular lymphoma who received at least two prior lines…
Data from the TRANSCEND-FL trial support the accelerated approval of lisocabtagene maraleucel in relapsed/refractory follicular lymphoma.
In this episode, Contributing Editor Samuel Wilson, MD, an assistant professor of hematology at the University of North Carolina, Chapel Hill, talks with Marc Blondon,…
Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy – given before and after surgery – significantly improved event-free survival (EFS) in patients with resectable…
Lisocabtagene maraleucel was approved by the FDA to treat adults with relapsed/refractory follicular lymphoma who were treated with 2 or more prior lines of systemic…
Olaparib, durvalumab, and fulvestrant produced a 66.7% 24-week PFS rate in patients with endocrine-resistant ER-positive, HER2-negative breast cancer.